Full text
Earnings transcript
Read the complete earnings call transcript.
MRK
Merck & Co., Inc.
$119.6
0.08
(0.07%)
| Exchange: | NYSE |
| Market Cap: | 295.391B |
| Shares Outstanding: | 2.571B |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Robert Davis | |||||
| Full Time Employees: | 73000 | |||||
| Address: |
| |||||
| Website: | https://www.merck.com |
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck’s extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 60,115,000 | 64,168,000 | 64,926,000 |
| Gross Profit | 43,989,000 | 48,975,000 | 46,731,000 |
| EBITDA | 6,907,000 | 25,706,000 | 29,324,000 |
| Operating Income | 2,954,000 | 20,221,000 | 23,486,000 |
| Net Income | 365,000 | 17,117,000 | 18,254,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 106,675,000 | 117,106,000 | 0 |
| Total Liabilities | 69,040,000 | 70,734,000 | -51,907,000 |
| Total Stockholders Equity | 37,581,000 | 46,313,000 | 51,907,000 |
| Total Debt | 36,268,000 | 38,270,000 | 0 |
| Cash and Cash Equivalents | 6,841,000 | 13,242,000 | 0 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 13,006,000 | 21,468,000 | 0 |
| Capital Expenditure | -3,863,000 | -3,372,000 | 0 |
| Free Cash Flow | 9,143,000 | 18,096,000 | 0 |
| Net Income | 365,000 | 17,133,000 | 18,254,000 |
| Net Change in Cash | -5,864,000 | 6,409,000 | -13,318,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 73,143,844.179 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 75,638,654.197 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 74,242,713.468 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 39,504,648.578 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 40,852,083.815 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 40,098,142.748 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 24,552,605.349 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 25,646,208.890 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 25,034,300.329 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 12,335,873.989 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 12,756,629.316 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 12,521,200.769 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 9.990 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 10.230 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 9.790 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Diversified revenue tracking across product categories and geographic regions supports resilience in core pharmaceutical operations.
- Strong balance sheet metrics including total assets, cash equivalents, and stockholders' equity provide financial flexibility.
- Consistent free cash flow generation alongside operating cash flow and capital expenditure monitoring enables sustained investment capacity.
- Established full-time employee base and CEO leadership structure underpin operational scale in the healthcare sector.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates MRK intrinsic value between $104.79 – $1,415.03 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about MRK valuation
Is Merck & Co., Inc. (MRK) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Merck & Co., Inc. (MRK) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is MRK a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MRK trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is MRK’s P/E ratio?
You can see MRK’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for MRK?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is MRK a good long-term investment?
Whether MRK fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
MRK
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.07
Trading Metrics:
| Open: | 120.03 | Previous Close: | 119.52 | |
| Day Low: | 118 | Day High: | 120.5 | |
| Year Low: | 76.66 | Year High: | 125.14 | |
| Price Avg 50: | 116.19 | Price Avg 200: | 104.1 | |
| Volume: | 9.667M | Average Volume: | 9.511M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeMRK full analysis
Hey everyone, welcome back to the channel where we break down stocks like we're chatting over coffee about what really matters for your portfolio. Today we're diving deep into Merck & Co., ticker MRK, a healthcare heavyweight that's been turning heads lately with its performance and pipeline. Let's kick things off with the bigger picture. Merck has shown solid momentum recently, with shares attracting plenty of investor interest after a string of earnings beats. The stock has delivered strong returns…
